Equity Long-Short Analyst

Pyari Menon

Equity Bottom-Up

Clinuvel Pharmaceuticals / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clinuvel-pharmaceuticals-limited" target="_blank" data-smartkarma-citation="entities:17714:1" rel="noopener">Clinuvel Pharmaceuticals (CUV AU)'s</a> Scenesse is the only approved erythropoietic protoporphyria (EPP) treatment. Patent protection and orphan drug status solidifies Clinuvel’s market position.</li>
<li>Clinuvel is expanding Scenesse's (afamelanotide) use and developing and testing additional products for clinical and photo-cosmetic use. </li>
<li>Profitability metrics and growth are solid and cash position strong to support R&amp;D for trials and new product development.</li>
</ul>



Clinuvel Pharmaceuticals (CUV AU)'s Scenesse is the only approved erythropoietic protoporphyria (EPP) treatment. Patent protection and orphan drug status solidifies Clinuvel’s market position.
Clinuvel is expanding Scenesse's (afamelanotide) use and developing and testing additional products for clinical and photo-cosmetic use. 
Profitability metrics and growth are solid and cash position strong to support R&amp;D for trials and new product development.


Clinuvel: A Big Future in Skin Disease Treatment

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Aug 9th (reported today) which has an aggregated short interest worth USD20.6bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in CSL, Qbe Insurance, Macquarie, Agl Energy, Telstra.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Aug 9th (reported today) which has an aggregated short interest worth USD20.6bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in CSL, Qbe Insurance, Macquarie, Agl Energy, Telstra.


ASX Short Interest Weekly (Aug 9th): CSL, Qbe Insurance, Macquarie, Agl Energy, Telstra

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Aug 2nd (reported today) which has an aggregated short interest worth USD20.4bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Westgold Resourc, Seek, Paladin Energy, Fortescue, ANZ, Altium.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Aug 2nd (reported today) which has an aggregated short interest worth USD20.4bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Westgold Resourc, Seek, Paladin Energy, Fortescue, ANZ, Altium.


ASX Short Interest Weekly (Aug 2nd): Westgold Resourc, Seek, Paladin Energy, Fortescue, ANZ, Altium

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jul 26th (reported today) which has an aggregated short interest worth USD20.3bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Woodside Energy, Fortescue, ANZ, CSL, Altium, Telstra.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jul 26th (reported today) which has an aggregated short interest worth USD20.3bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Woodside Energy, Fortescue, ANZ, CSL, Altium, Telstra.


ASX Short Interest Weekly (Jul 26th): Woodside Energy, Fortescue, ANZ, CSL, Altium, Telstra

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jul 19th (reported today) which has an aggregated short interest worth USD20.2bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Fortescue, Bluescope Steel, Brambles.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jul 19th (reported today) which has an aggregated short interest worth USD20.2bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Fortescue, Bluescope Steel, Brambles.


ASX Short Interest Weekly (Jul 19th): Fortescue, Bluescope Steel, Brambles

Australia

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company. The company focused on developing dermatology pharmaceutical products for a range of UV-related skin disorders. Clinuvel's work aims at preventing the symptoms of diseases related to harmful UV radiation.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clinuvel Pharmaceuticals (CUV AU)

Clinuvel: A Big Future in Skin Disease Treatment

Clinuvel is a strong investment due to its monopoly on the only approved EPP treatment (Scenesse), patent protection, orphan drug status, solid...

Pyari Menon

ASX Short Interest Weekly (Aug 9th): CSL, Qbe Insurance, Macquarie, Agl Energy, Telstra

We analyzed ASX short interest report for the past week and highlight short interest changes in CSL, Qbe Insurance, Macquarie, Agl Energy, Telstra.

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Aug 2nd): Westgold Resourc, Seek, Paladin Energy, Fortescue, ANZ, Altium

We analyzed ASX short interest report for the past week and highlight short interest changes in Westgold Resourc, Seek, Paladin Energy, Fortescue,...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Jul 26th): Woodside Energy, Fortescue, ANZ, CSL, Altium, Telstra

We analyzed ASX short interest report for the past week and highlight short interest changes in Woodside Energy, Fortescue, ANZ, CSL, Altium, Telstra.

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Jul 19th): Fortescue, Bluescope Steel, Brambles

We analyzed ASX short interest report for the past week and highlight short interest changes in Fortescue, Bluescope Steel, Brambles.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)